TPR and cancer: The treatment of OvCAR3 and OvCAR3-EpCAM-KO cells with EpCAM-ReTARGTPRIFNαR149A (0.0001–10 nM) in the absence of TPR-specific CD8pos T cells for 8 d selectively inhibited cancer cell proliferation in both an EpCAM-restricted and dose-dependent manner, whereas similar treatment with EpCAM-ReTARGTPR or rhIFNα failed to do so.